ライフサイエンスコーパス: hepatitis A

1 ymptoms could increase the risk of relapsing hepatitis A.

2 ) times higher odds of death associated with hepatitis A.

3 eventable contributing cause of death due to hepatitis A.

4 thin 14 days after exposure to patients with hepatitis A.

5 lated from northern Mexican resident(s) with hepatitis A.

6 is A, and restaurant workers were tested for hepatitis A.

7 d this unusually large foodborne outbreak of hepatitis A.

8 ffective strategy to reduce the incidence of hepatitis A.

9 counties, and communities with high rates of hepatitis A.

10 ) times higher odds of death associated with hepatitis A.

11 re or present in sera from humans with acute hepatitis A.

12 vaccination of toddlers effectively controls hepatitis A.

13 serum samples from patients with acute Hepatitis A (12/ 75 in Tel-Aviv and 31 patients hospital

14 78 (59.8%) were immune or vaccinated against hepatitis A, 122 (7.5%) had negative hepatitis A antibod

15 impaired antibody responses after receipt of hepatitis A (54%) and TT (86%) vaccines were considered

16 98 (56.3%) were immune or vaccinated against hepatitis A, 659 (12.4%) had negative hepatitis A antibo

17 viral isolates from 3 patients with cases of hepatitis A acquired in Mexico.

18 table diseases targeted since 1980 including hepatitis A, acute hepatitis B, Hib, and varicella.

19 A large outbreak of hepatitis A affected individuals in several Australian s

20 focus on the need to assess protection from hepatitis A among adults, including those with liver dis

21 iority was met, the slightly higher rates of hepatitis A among vaccine recipients may indicate a true

22 avrix), hepatitis B vaccine (Engerix-B), and hepatitis A and B combination vaccine (Twinrix) were stu

23 We describe immunity and vaccination against hepatitis A and B in chronic hepatitis patients from the

24 The incidence of acute hepatitis A and B infection has declined significantly,

25 Hepatitis A and B infections occasionally elicit a power

26 nitions, including requirements for negative hepatitis A and B laboratory results.

27 ting safe IDU practices, drug treatment, and hepatitis A and B vaccination should be key components o

28 ting safe IDU practices, drug treatment, and hepatitis A and B vaccinations should be key components

29 Hepatitis A and B vaccines are effective in preventing s

30 tivated glycoprotein 120-depleted HIV-1, and hepatitis A and B vaccines.

31 aptive immune responses to HCV with those to hepatitis A and B viruses, we suggest that prolonged inn

32 Nonimmune patients need vaccinations against hepatitis A and B, and alcohol abstinence is critical.

33 ude childhood vaccine-preventable illnesses, hepatitis A and B, tuberculosis, malaria, and typhoid fe

34 t multiple pathogenic RNA viruses, including hepatitis A and C viruses, dengue virus and Zika virus.

35 and lyssaviruses and viruses associated with hepatitis A and E.

36 tes and independent predictors of history of hepatitis A and hepatitis B (HepA and HepB) vaccinations

37 Professional societies recommend hepatitis A and hepatitis B immunization for individuals

38 iven the public health implications of acute hepatitis A and hepatitis B in patients with CLD, better

39 Advances have been made in the prevention of hepatitis A and hepatitis E.

40 Hepatitis A and typhoid were the most frequently adminis

41 ses being found with acetaminophen overdose, hepatitis A, and ischemia (approximately 60% spontaneous

42 rom patients with laboratory confirmation of hepatitis A, and restaurant workers were tested for hepa

43 Measles, hepatitis A, and tuberculosis have been associated with

44 mmunoglobin G (IgG) antibodies to H. pylori, hepatitis A antibodies (a marker of low socioeconomic st

45 n faecal samples, Der p 1 levels in bedding, hepatitis A antibodies, serum cholinesterase (a marker o

46 heir effectiveness, and of seroprevalence of hepatitis A antibody and anti-HB surface antibody.

47 against hepatitis A was defined by positive hepatitis A antibody or documented vaccination.

48 gainst hepatitis A, 659 (12.4%) had negative hepatitis A antibody tests, and 1671 (31.4%) had no test

49 against hepatitis A, 122 (7.5%) had negative hepatitis A antibody tests, and 535 (32.7%) had no testi

50 uenza virosomal vaccines - for influenza and hepatitis A - are registered for human use, and the viro

51 Rates of hospitalization for hepatitis A as a principal diagnosis decreased from 0.72

52 We calculated rates of hospitalizations with hepatitis A as the principal discharge diagnosis and rat

53 rtality rates for decedents with and without hepatitis A, B, and C virus (HAV, HBV, and HCV) and rela

54 n exclusion of other causes, including viral hepatitis A, B, and C.

55 sults did not differ by alcohol consumption; hepatitis A, B, or C serologic status; recent infection;

56 The severity of acute or chronic hepatitis A, B, or C was not influenced by coexisting SE

57 accination during a recent outbreak of acute hepatitis A between 2015 and 2017, a 1:4 case-control st

58 of 330 factors, including infectious (e.g., hepatitis A), biochemical (e.g., carotenoids, high-densi

59 Hepatitis A causes approximately half of the cases of vi

60 lso prevented Concanavilin A (Con A) induced hepatitis, a CD4(+) T cell-mediated animal model of live

61 ding of the epidemiology and transmission of hepatitis A combined with the availability of effective

62 ients reported contact with a person who had hepatitis A, compared with 2 (2%) control subjects (odds

63 g daclizumab HYP) died because of autoimmune hepatitis; a contributory role of daclizumab HYP could n

64 ey were randomly assigned to PCV (n = 49) or hepatitis A (control, n = 50) vaccination and inoculated

65 U.S. residents hospitalized with a principal hepatitis A diagnosis and accompanying secondary diagnos

66 Hepatitis A disease and resulting hospitalizations could

67 Developing countries with an increasing hepatitis A disease burden may target vaccination to spe

68 nfection with HAV and higher risk for severe hepatitis A disease outcomes compared with those not exp

69 her risk of infection with HAV and of severe hepatitis A disease outcomes compared with those not exp

70 We assessed risk factors for severe hepatitis A disease outcomes, including hospitalization

71 pment of symptoms consistent with autoimmune hepatitis, a disease previously found to result from dys

72 Hepatitis A-E serology was measured, including hepatitis

73 es/rhinoviruses, measles virus, mumps virus, Hepatitis A-E Virus, Chikungunya virus, dengue virus, an

74 scents, and certain high-risk adults against hepatitis A, economic analyses of hepatitis A vaccinatio

75 s A vaccination programs in areas undergoing hepatitis A epidemiologic transition.

76 outbreaks and increase our understanding of hepatitis A epidemiology in the United States.

77 Epidemic-assistance investigations for hepatitis A, gastrointestinal and foodborne infectious d

78 reas of the United States with high rates of hepatitis A has been recommended.

79 The incidence of hepatitis A has declined dramatically during the era of

80 Hepatitis A (HAV) and hepatitis B (HBV) vaccination in p

81 Vaccination against hepatitis A (HAV) has been shown to be safe and effectiv

82 d can be caused by several agents, including hepatitis A (HAV), B (HBV), and C (HCV) virus.

83 Viruses studied were hepatitis A (HAV), hepatitis B (HBV), varicella zoster v

84 ation efforts, including universal childhood hepatitis A (HepA) vaccination recommendations in 2006,

85 The safety and immunogenicity of inactivated hepatitis A (HepA) vaccine was assessed in 133 hepatitis

86 and new information on pertussis, varicella, hepatitis A, hepatitis B, measles, and rotavirus vaccina

87 We describe changes in primary hepatitis A hospitalization rates in the United States f

88 The percentage of hepatitis A hospitalizations covered by Medicare increas

89 Hospitalization rates for hepatitis A illness have declined significantly from 200

90 Hepatitis A illness severity increases with age.

91 One indicator of hepatitis A illness severity is whether persons are hosp

92 xposure prophylaxis can successfully prevent hepatitis A illness when a specific product is identifie

93 relatively long-term protection conferred by hepatitis A immune globulin, the efficacy of a single in

94 an hepatologists but screened more often for hepatitis A immunity (P = .028).

95 ce/ethnicity, health insurance coverage, and hepatitis A immunity by anti-HBc status.

96 ce/ethnicity, health insurance coverage, and hepatitis A immunity by anti-HBc status.

97 9.8% reported prior-year IDU and 28.5% had a hepatitis A immunity.

98 , 19.8% reported past year IDU and 28.5% had hepatitis A immunity.

99 Since 1999, routine hepatitis A immunization of children in areas of the Uni

100 Low rates of hepatitis A in both groups indicate that hepatitis A vac

101 s and from individuals concurrently ill with hepatitis A in non-outbreak settings in the United State

102 The risks of hepatitis A in patients with chronic liver disease have

103 Persons hospitalized for hepatitis A in recent years are older and more likely to

104 ng geographic variations in the incidence of hepatitis A in the United States.

105 ines have dramatically reduced the burden of hepatitis A in the United States.

106 ldhood vaccination appears to have decreased hepatitis A incidence among children and adults and cont

107 accination (UTV) introduced in 1999, reduced hepatitis A incidence in Israel from 50.4 to <1.0/100,00

108 Hepatitis A infection did not influence the immune respo

109 Severe hepatitis A infection is an infrequent but well-recogniz

110 stances of laboratory-confirmed, symptomatic hepatitis A infection occurring between 15 and 56 days a

111 nty of San Diego investigated an outbreak of hepatitis A infections primarily among people experienci

112 tion of children in areas with high rates of hepatitis A is a cost-effective strategy to reduce the i

113 Hepatitis A is a major public health problem in the Unit

114 Hepatitis A is a vaccine-preventable viral disease trans

115 ifylline is recommended for severe alcoholic hepatitis, a life-threatening disease.

116 nza, measles, mumps, and rubella, varicella, hepatitis A, meningococcal conjugate, human papillomavir

117 Hepatitis A mortality rates have declined over the past

118 Overall, 1436 deaths due to hepatitis A occurred, averaging 96 annually (range, 142

119 infection was significantly associated with hepatitis A (odds ratio [OR], 3.3; 95% confidence interv

120 o documented immunity or vaccination against hepatitis A or hepatitis B.

121 In November 2003, a large hepatitis A outbreak was identified among patrons of a s

122 e of semidried tomatoes as the cause of this hepatitis A outbreak.

123 surveillance would improve the detection of hepatitis A outbreaks and increase our understanding of

124 portant role in the detection and control of hepatitis A outbreaks and requires the application of ra

125 s can link geographically separate foodborne hepatitis A outbreaks but have not been used while field

126 in length-of-stay or in-hospital deaths from hepatitis A over time were found, but persons with liver

127 ls were increased in patients with alcoholic hepatitis, a prototypic acute-on-chronic condition; and

128 ts have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member s

129 ldhood ear infections, myringotomy, measles, hepatitis A, rheumatic fever, common colds, rubella and

130 Hepatitis A RNA was detected in 22 samples of semidried

131 6 [1.00-1.59], p=0.05), and was unrelated to hepatitis A seropositivity or cholinesterase concentrati

132 rvey and vaccination, 25 children contracted hepatitis A subclinically (>8000 mIU/mL anti-HAV).

133 molecular epidemiologic methods into routine hepatitis A surveillance would improve the detection of

134 ety of other causes, but not including viral hepatitis A through E.

135 We aimed to document the prevalence of viral hepatitis A to E in Hong Kong.

136 exclusively by sera collected at the time of hepatitis, a total of 240 spots were identified, corresp

137 We measured the frequency of indications for hepatitis A vaccination according to Advisory Committee

138 We measured the frequency of indications for hepatitis A vaccination according to Advisory Committee

139 HAV) on the duration of seropositivity after hepatitis A vaccination during infancy and early childho

140 Hepatitis A vaccination has dramatically reduced the inc

141 d a literature review of previous studies on hepatitis A vaccination in immunocompromised patients.

142 Hepatitis A vaccination is effective in preventing disea

143 Hepatitis A vaccination is recommended for patients with

144 Routine hepatitis A vaccination of children in areas with high r

145 dren are appropriate targets for sustainable hepatitis A vaccination programs in areas undergoing hep

146 hildren who initiated a two-dose inactivated hepatitis A vaccination series at ages 6 months (group 1

147 ts against hepatitis A, economic analyses of hepatitis A vaccination were identified through searches

148 owed moderate to good serologic responses to hepatitis A vaccination, but may need more time to devel

149 patients recorded other ACIP indications for hepatitis A vaccination.

150 25 years, 1:1, to receive HPV vaccination or hepatitis A vaccination.

151 ion to add homelessness as an indication for hepatitis A vaccination.

152 5, 7, and 10 years after the second dose of hepatitis A vaccination.

153 urth of PEH had no other ACIP indication for hepatitis A vaccination.

154 munocompromised patients who received 1 or 2 hepatitis A vaccinations between January 2011 and June 2

155 high doses of immunosuppressive drugs, fewer hepatitis A vaccinations, and a short interval between v

156 ricomponent acellular pertussis vaccine or a hepatitis A vaccine (control) and were monitored for 2.5

157 age, in a 1:1 ratio, to receive the QIV or a hepatitis A vaccine (control).

158 In this study, AE profiles induced by hepatitis A vaccine (Havrix), hepatitis B vaccine (Enger

159 SmithKline, Rixensart, Belgium) or a control hepatitis A vaccine (modified preparation of Havrix, Gla

160 04 candidate vaccine (n = 1088) or a control hepatitis A vaccine (n = 1101) over 6 months.

161 Persistence of seropositivity conferred by hepatitis A vaccine administered to children <2 years of

162 Hepatitis A vaccine administered to persons after exposu

163 Among these contacts, 568 received hepatitis A vaccine and 522 received immune globulin.

164 of hepatitis A in both groups indicate that hepatitis A vaccine and immune globulin provided good pr

165 The seropositivity induced by hepatitis A vaccine given to children <2 years of age pe

166 Since the mid-1990s, hepatitis A vaccine has been recommended for US children

167 Hepatitis A vaccine has similar efficacy to immune globu

168 ssess the safety and efficacy of inactivated hepatitis A vaccine in OLT recipients.

169 The response to the hepatitis A vaccine is optimal when targeted to patients

170 receive one standard age-appropriate dose of hepatitis A vaccine or immune globulin within 14 days af

171 In this population, hepatitis A vaccine was highly effective in preventing d

172 s an adjuvant; control subjects received the hepatitis A vaccine, at a dose of 720 enzyme-linked immu

173 , the first dose was 720 ELISA units (EU) of hepatitis A vaccine, readministered at 1 and 12 months a

174 gned (1:1) to HPV-16/18 vaccine or a control hepatitis A vaccine, via an internet-based central rando

175 who responded to a 3-dose primary series of hepatitis A vaccine.

176 l subjects reported a willingness to receive hepatitis A vaccine.

177 HPV 16/18 AS04-adjuvanted vaccine or control hepatitis A vaccine.

178 ized into three groups to receive a two-dose hepatitis A vaccine: group 1 at 6 and 12 months, group 2

179 tivized measures (largest difference was for hepatitis A vaccine: odds ratio, 0.34; 99.88% CI, 0.31-0

180 Hepatitis A vaccines are highly immunogenic in healthy p

181 combined with the availability of effective hepatitis A vaccines have dramatically reduced the burde

182 ase have been confirmed, and the efficacy of hepatitis A vaccines in these patients has been proven.

183 influenzae type b (Hib), acute hepatitis B, hepatitis A, varicella, Streptococcus pneumoniae, and sm

184 A high seroprevalence of hepatitis A virus (81%) among human immunodeficiency vir

185 Prevalence of antibodies to hepatitis A virus (anti-HAV) and hepatitis E virus (anti

186 fter vaccination were tested for antibody to hepatitis A virus (anti-HAV) by ELISA.

187 f passively transferred maternal antibody to hepatitis A virus (anti-HAV) on the duration of seroposi

188 Herein, we show that hepatitis A virus (HAV) 3C protease (3Cpro) cleaves NEMO

189 Vaccination provides long-term immunity to hepatitis A virus (HAV) among the general population, bu

190 lages in rural Alaska between 2 epidemics of hepatitis A virus (HAV) and after the second epidemic (1

191 Hepatitis A virus (HAV) and hepatitis C virus (HCV) are

192 a child who died of FVH upon infection with hepatitis A virus (HAV) at age 11 yr and who was homozyg

193 Hepatitis A virus (HAV) has been adapted to grow efficie

194 Replication of hepatitis A virus (HAV) in cultured cells is inefficient

195 r highly specific and sensitive detection of hepatitis A virus (HAV) in food and water are of particu

196 Acute liver failure (ALF) due to hepatitis A virus (HAV) infection is an uncommon but pot

197 We describe a murine model of hepatitis A virus (HAV) infection that recapitulates cri

198 Hepatitis A virus (HAV) infection typically resolves wit

199 on has dramatically reduced the incidence of hepatitis A virus (HAV) infection, but new infections co

200 n of HEV infection has broad similarities to hepatitis A virus (HAV) infection, with most cases being

201 Hepatitis A virus (HAV) infects African green monkey kid

202 Hepatitis A virus (HAV) infects African green monkey kid

203 Remarkably, the hepatitis A virus (HAV) IRES requires eIF4E for its tran

204 Hepatitis A virus (HAV) is a common infection that is tr

205 Hepatitis A virus (HAV) is a hepatotropic picornavirus t

206 Hepatitis A virus (HAV) is an ancient and ubiquitous hum

207 Hepatitis A virus (HAV) is an hepatotropic human picorna

208 Unlike other picornaviruses, hepatitis A virus (HAV) is cloaked in host membranes whe

209 Hepatitis A virus (HAV) is naturally transmitted by the

210 The genetic relatedness of hepatitis A virus (HAV) isolates was determined to ident

211 The current Hepatitis A virus (HAV) molecular epidemiology in Israel

212 Coinfection with hepatitis A virus (HAV) or hepatitis B virus (HBV) in pa

213 The human homolog of TIM-1 is the hepatitis A virus (HAV) receptor, which may explain the

214 Hepatitis A virus (HAV) remains enigmatic, despite 1.4 m

215 and accurate molecular diagnostic tools for hepatitis A virus (HAV) RNA detection, subgenotype ident

216 Hepatitis A virus (HAV) superinfection in persons with h

217 Hepatitis A virus (HAV) superinfection is associated wit

218 However, hepatitis A virus (HAV) temporarily inhibits Treg-cell f

219 tion between homelessness and infection with hepatitis A virus (HAV) using a test-negative study desi

220 l responses (Seroresponse) and durability of hepatitis A virus (HAV) vaccination are reduced among hu

221 or Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at

222 Hepatitis A virus (HAV) vaccination is recommended in ch

223 Universal 2-dose hepatitis A virus (HAV) vaccination of toddlers effectiv

224 h men (MSM) receiving two and three doses of hepatitis A virus (HAV) vaccine and HIV-uninfected MSM r

225 the safety and immunogenicity of 2 doses of hepatitis A virus (HAV) vaccine followed by a booster do

226 lity of virulent hepatitis E virus (HEV) and hepatitis A virus (HAV) was compared.

227 Among these, hepatitis A virus (HAV), a common cause of acute hepatit

228 Here, we show that hepatitis A virus (HAV), a hepatotropic picornavirus, ab

229 of positive-strand RNA viruses that includes hepatitis A virus (HAV), an ancient human pathogen that

230 Hepatitis A virus (HAV), an atypical member of the Picor

231 on, all participants were vaccinated against hepatitis A virus (HAV), and the increase of antibody ti

232 Many 'non-enveloped' viruses, including hepatitis A virus (HAV), are released non-lytically from

233 IgG antibodies to cytomegalovirus (CMV), hepatitis A virus (HAV), herpes simplex virus type 1 (HS

234 d States was surveyed for antibody titers to hepatitis A virus (HAV), measles virus (MeV), and cytome

235 During infection with the hepatitis A virus (HAV), most patients develop mild or a

236 Human wild-type (wt) hepatitis A virus (HAV), the causative agent of acute he

237 y a stem-loop structure with cre function in hepatitis A virus (HAV), the type species of this genus,

238 ial serological studies were consistent with hepatitis A virus (HAV), with prozone phenomenon.

239 (HepA) vaccination recommendations in 2006, hepatitis A virus (HAV)-associated outbreaks have increa

240 rticipate in cargo delivery from exosomes of hepatitis A virus (HAV)-infected cells (exo-HAV) by clat

241 se and control subjects were also tested for hepatitis A virus (HAV).

242 These results pertain to hepatitis A virus (HAV).

243 e period were negative for IgM antibodies to hepatitis A virus (HAV).

244 have had exposure and resultant immunity to hepatitis A virus (HAV).

245 udies show that some picornaviruses, notably hepatitis A virus (HAV; genus Hepatovirus) and some memb

246 passively transferred maternal antibodies to hepatitis A virus (maternal anti-HAV) may lower the infa

247 respond to a recall antigen and neoantigen (hepatitis A virus [HAV] vaccine) after 3 vaccinations.

248 andomization, 1414 (31%) were susceptible to hepatitis A virus and 1090 were eligible for the per-pro

249 However, recent work on hepatitis A virus and hepatitis E virus challenges this

250 multiple human maladies, yet currently, only hepatitis A virus and poliovirus can be controlled with

251 es of the encephalomyocarditis virus and the hepatitis A virus are both type III substrates for the m

252 lar injury [KIM-1 (kidney injury molecule-1)/Hepatitis A virus cellular receptor 1 ( Havcr1)] were ev

253 e toxin binds to protein receptors including hepatitis A virus cellular receptor 1 (HAVCR1), but the

254 The hepatitis A virus cellular receptor 1 (HAVCR1/TIM1), a m

255 expression of the inhibitory receptors PD-1, hepatitis A virus cellular receptor 2 (TIM3), lymphocyte

256 in-containing protein 3 (TIM3, also known as hepatitis A virus cellular receptor 2), and their respec

257 munized sequentially with tetanus toxoid and hepatitis A virus failed to develop antibody to either a

258 Sequences of hepatitis A virus from all 170 patients who were tested

259 Hepatitis A virus genotype IB was identified in 144 of 1

260 Hepatitis A virus genotype IB, uncommon in the Americas,

261 dministered to persons after exposure to the hepatitis A virus has not been compared directly with im

262 actions can help rapidly detect and control hepatitis A virus illness caused by imported food.

263 ecovered from specimens from 117 people with hepatitis A virus illness.

264 To better understand transmission of hepatitis A virus in such countries, the authors prospec

265 itis B virus now joins hepatitis C virus and hepatitis A virus in targeting the same innate immune re

266 ica, DRB1*1301 is associated with protracted hepatitis A virus infection which may enhance exposure t

267 In May, 2013, an outbreak of symptomatic hepatitis A virus infections occurred in the USA.

268 84- angstrom resolution crystal structure of hepatitis A virus IRES domain V (dV) in complex with a s

269 erved as controls, with infections by either hepatitis A virus or hepatitis B virus (HBV), or a nonin

270 s community was largely spared from a recent hepatitis A virus outbreak in San Diego, California.

271 ing information, and did genetic analysis of hepatitis A virus recovered from patients' serum and sto

272 tion since proteins of hepatitis C virus and hepatitis A virus similarly bind IPS-1 and target it for

273 lace, and postexposure prophylaxis with both hepatitis A virus vaccine and immunoglobulin was provide

274 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline and assigned 3304 y

275 ore reactions at the injection site than the hepatitis A virus vaccine and saline.

276 Symptomatic infection with hepatitis A virus was confirmed in 25 contacts receiving

277 No hepatitis A virus was detected in product B.

278 Hepatitis A virus was sequenced from serologic specimens

279 We conclude that for species such as hepatitis A virus with high levels of sequence conservat

280 rhinovirus, encephalomyocarditis virus, and hepatitis A virus) are morphologically similar, comprisi

281 , Chlamydia pneumoniae, Helicobacter pylori, hepatitis A virus, and herpes simplex virus-1 were measu

282 enteric viruses, such as Human Norovirus and Hepatitis A Virus, are readily transmitted via the fecal

283 cally linked to asthma and is a receptor for hepatitis A virus, but the endogenous ligand of TIM-1 is

284 Tuberculosis organisms, hepatitis A virus, hepatitis B virus, and measles virus

285 l bacteria in the gastrointestinal tract and hepatitis A virus, may normally induce the development o

286 ad elevated titers of antibody to H. pylori, hepatitis A virus, rotavirus, and malaria at the outset,

287 unoglobulins A (IgA), G (IgG), and M (IgM)], hepatitis A virus, rotavirus, tetanus toxoid (IgG), and

288 patitis A (HepA) vaccine was assessed in 133 hepatitis A virus-seronegative, human immunodeficiency v

289 ths were Salmonella Typhi, Taenia solium and hepatitis A virus.

290 fectively prevented with vaccination against hepatitis A virus.

291 rent infection as the community reservoir of hepatitis A virus.

292 e genome is conserved among strains, such as hepatitis A virus.

293 solate, respectively, of the HM175 strain of hepatitis A virus.

294 Immunity against hepatitis A was defined by positive hepatitis A antibody

295 ath certificates from 1990 to 2004 for which hepatitis A was listed as the underlying cause of death

296 een November 1998 and May 1999, 136 cases of hepatitis A were reported in Columbus, Ohio.

297 In 2003, outbreaks of foodborne hepatitis A were reported in multiple states.

298 nderstanding, recommendations for control of hepatitis A were updated in 1999 to include routine vacc

299 s known to be highly effective in preventing hepatitis A when given within 2 weeks after exposure to

300 comparing patients with laboratory-confirmed hepatitis A with control subjects who tested negative fo